Press Room

Article / Dec 01, 2008

Family Owned Businesses

Chemistry Today, December 2008

Private companies usually have their shareholders meet every Sunday lunch, shop talk is kept to a minimum so as not to offend the “in-laws” and siblings not involved in the business.
Family owned companies are involved in management and get remunerated by far more than just dividends. The reputation that comes with a company that does well, that is a highly sought-after employer, that leads in innovation, in environmental thinking and international expansion, that does things right - rubs onto the family. For a family to be leading a business that is a role model brings a non-monetary compensation that makes this tight-knit group far richer than any stock market investor could ever be. Can you imagine the pride of a family where the business it owns addresses the capacity needs for the only paediatric HIV protease inhibitor? or the most innovative (avian) flu medicine?

Full version of Family owned businesses article

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026